A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancerLuca Malorni, Ilenia Migliaccio|Oncotarget|2016Cited by 170
Development of Resistance to Targeted Therapies Transforms the Clinically Associated Molecular Profile Subtype of Breast Tumor XenograftsChad J. Creighton, Rachel Schiff, Suleiman Massarweh et al.|Cancer Research|2008Cited by 138
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?Chiara Corti, Carmen Criscitiello, Carmine De Angelis et al.|Cancer Treatment Reviews|2023Cited by 54
Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncologyMichelino De Laurentiis, Sabino De Placido, Giuseppe Cancello et al.|Annals of Oncology|2005Cited by 49
Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes ResistanceLuca Malorni, Rachel Schiff, Mario Giuliano et al.|Molecular Cancer Research|2016Cited by 49